Small Cell Lung Cancer

Consolidation treatment with durvalumab after concurrent chemoradiation led to a survival benefit vs placebo for patients with limited-stage small cell lung cancer, leading researchers to argue for a new standard of care in this setting.

In an in-person Community Case Forum event in partnership with the North Carolina Oncology Association and South Carolina Oncology Society, Daniel Carrizosa, MD, MS, discussed the use of the immunotherapies durvalumab and atezolizumab in patients with small cell lung cancer.

In an interview with Targeted Oncology, Joe Leach, MD, highlighted the current state and future prospects of treating patients with small cell lung cancer.

The FDA accelerated approval of tarlatamab makes it the first bispecific T-cell engager therapy for a major solid tumor.

Phase 1 of the Acclaim-3 study evaluating quaratusugene ozeplasmid plus atezolizumab in patients with extensive-stage small cell lung cancer has enrolled and dosed its first patient.

Ariel Lopez-Chavez, MD, emphasizes the critical need for improved second-line therapies in small cell lung cancer.

SNB-101, a nanoparticle drug for small cell lung cancer, received a fast track designation from the FDA for expedited development and review.

Ariel Lopez-Chavez, MD, discusses ongoing research in the small cell lung cancer space.

Updated guidelines for small cell lung cancer were developed with an expert panel assembled by the American Society of Clinical Oncology and Ontario Health.

Ariel Lopez-Chavez, MD, discusses the potential of tarlatamab and its use in the frontline setting for the treatment of patients with small cell lung cancer.

Adding tislelizumab to chemotherapy improved overall survival and progression-free survival in patients with extensive-stage small cell lung cancer, according to findings from a phase 3 study.

The phase 3 CONVERT study suggests that twice-daily radiotherapy remains the standard for limited-stage small cell lung cancer due to its effectiveness and lower associated toxicity compared to the once-daily approach.

Adding low-dose radiotherapy to standard-of-care durvalumab and chemotherapy led to survival benefits among patients with extensive-stage small cell lung cancer.

PT217 is a first-in-class treatment targeting DLL3 and CD47 for patients with extensive-stage small cell lung cancer.

Ariel Lopez-Chavez, MD, discusses some of the research on evaluating PD-L1 therapy for patients with small cell lung cancer.

Findings from a post hoc analysis of lurbinectedin for the treatment of small cell lung cancer showed that the agent was more effective and less toxic than topotecan.

Ariel Lopez-Chavez, MD, provided insights into the current landscape of small cell lung cancer treatment, highlighting approved options and ongoing research.

A phase 2 trial is underway to assess alisertib for extensive-stage small cell lung cancer treatment, aiming to enroll up to 60 patients.

Patients with extensive-stage small cell lung cancer experienced longer rates of survival when treated with atezolizumab induction and maintenance therapy vs placebo.

A study has identified a genetic mechanism, DHX9, making small cell lung cancer responsive to immunotherapy. This is a pivotal breakthrough for treatment of a historically resistant disease.

The FDA has granted priority review approval to tarlatamab for advanced small cell lung cancer based on encouraging results in a phase 2 clinical trial.

Antibody-based DLL3-targeting agents and antibody-drug conjugates present exciting treatment possibilities in small cell lung cancer, according to a presentation by Charles Rudin, MD, at the 18th Annual New York Lung Cancer Symposium.

During a Community Case Forum event in partnership with the South Carolina Oncology Society, Kathryn Mileham, MD, discussed the significance of the IMpower133 and CASPIAN trials for patients with extensive-stage small cell lung cancer.

In an interview with Targeted Oncology, Penn Medicine’s Qian Wang, MD, MPH, gives an in-depth overview of the molecular targets in the small cell lung cancer field.

THIO has received 2 prior orphan drug designations, and the agent has shown promise in preclinical studies for the treatment of glioblastoma.